Absence assistance system for multimedia-enabled communication systems
    4.
    发明授权
    Absence assistance system for multimedia-enabled communication systems 有权
    缺乏多媒体通信系统的辅助系统

    公开(公告)号:US08028016B2

    公开(公告)日:2011-09-27

    申请号:US11991825

    申请日:2006-08-24

    IPC分类号: G06F15/16 G06F15/173

    摘要: The absence assistance system for at least one multimedia-enabled communication system comprising a plurality of packet-oriented client communication systems, in which the packet-oriented client communication systems support at least in part different multimedia services and at least one multimedia service of a packet-oriented client communication system is in each case assigned to at least one communication subscriber, has in each case at least one absence assistance unit per packet-oriented client communication system, the packet-oriented client communication systems being connected to one another via a peer-to-peer transmission protocol. The absence assistance units manage, in the absence of a communication subscriber, the communication connections directed to the absent communication subscriber via the at least one assigned multimedia service.

    摘要翻译: 用于至少一个支持多媒体的通信系统的缺失辅助系统包括多个面向分组的客户端通信系统,其中面向分组的客户端通信系统至少部分地支持不同的多媒体服务和分组的至少一个多媒体服务 在每种情况下,定向客户端通信系统在每种情况下分配给至少一个通信用户,在每种情况下,每个面向每个客户端的客户端通信系统至少有一个不存在辅助单元,面向分组的客户端通信系统经由对等体彼此连接 对等传输协议。 缺席辅助单元在没有通信用户的情况下管理经由至少一个分配的多媒体服务指向缺席通信用户的通信连接。

    Macrolactone derivatives
    8.
    发明授权
    Macrolactone derivatives 有权
    麦芽糖内酯衍生物

    公开(公告)号:US08268775B2

    公开(公告)日:2012-09-18

    申请号:US12640273

    申请日:2009-12-17

    IPC分类号: A61K38/00 C09F1/00

    摘要: The disclosure relates to compounds of the formula (I): wherein R1, R2, R3, and R4 are as defined in the disclosure, or a pharmaceutically acceptable salt thereof; which is formed by the microorganism ST 201196 (DSM 18870); the use thereof for the treatment and/or prophylaxis of fungal disorders; medicaments containing a compound of formula (I); processes for production thereof; and the microorganism ST 201196 (DSM 18870).

    摘要翻译: 本公开涉及式(I)的化合物:其中R 1,R 2,R 3和R 4如本公开内容所定义,或其药学上可接受的盐; 其由微生物ST 201196(DSM 18870)形成; 其用于治疗和/或预防真菌病症的用途; 含有式(I)化合物的药物; 生产过程; 和微生物ST 201196(DSM 18870)。

    MACROLACTONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF CANCER
    9.
    发明申请
    MACROLACTONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF CANCER 审中-公开
    麦角酮衍生物,其生产方法及其用于治疗癌症的方法

    公开(公告)号:US20110306563A1

    公开(公告)日:2011-12-15

    申请号:US13139458

    申请日:2009-12-10

    CPC分类号: A61K31/395 C07K5/0808

    摘要: The present invention relates to the use of a compound of the formula (I), wherein X and Y independently of one another are OH, O—(C1-C6)-alkyl, NH2 or NH—(C1-C6)-alkyl, or X and Y together form a group —O— or wherein X and Y together form a further bond between the C atoms to which they are attached; R1 and R2 independently of one another are H, Cl or Br; R3 is H,(C1-C6)alkyl, C(═O)—(C1-C6)-alkyl or (C1-C6)-alkylene-NH—(C1-C6)-alkyl; R4 is H, (C1-C6)-alkyl or C(═O)—(C1-C6)-alkyl, and R5 is methyl or ethyl; or a physiologically tolerable salt of a compound of the formula (I), for the treatment and/or prophylaxis of cancer diseases, a pharmaceutical composition for the treatment and/or prophylaxis of cancer diseases comprising a compound of the formula (I), a compound of the formula (I) and a process for the preparation of the compound (I).

    摘要翻译: 本发明涉及式(I)化合物的用途,其中X和Y彼此独立地为OH,O-(C 1 -C 6) - 烷基,NH 2或NH-(C 1 -C 6) - 烷基, 或X和Y一起形成基团-O-或其中X和Y一起在它们所连接的C原子之间形成另外的键; R1和R2彼此独立地是H,Cl或Br; R3是H,(C1-C6)烷基,C(= O) - (C1-C6) - 烷基或(C1-C6) - 亚烷基-NH-(C1-C6) - 烷基; R4是H,(C1-C6) - 烷基或C(= O) - (C1-C6) - 烷基,R5是甲基或乙基; 或式(I)化合物的生理上可耐受的盐,用于治疗和/或预防癌症疾病,用于治疗和/或预防癌症疾病的药物组合物,其包含式(I)化合物, 式(I)的化合物和化合物(I)的制备方法。